FGFR3 and cancer: Although selective functional advantage of a mutation can be cancer-type specific (e.g. enrichment of FGFR3 mutations in BCa) and the distribution of attributable mutagenic processes vary from one cancer type to another (e.g. dominant APOBEC mutagenesis in BCa), 32% (14/44) of the APOBEC-associated hotspot mutations identified in BCa were also found in other cancer types with high APOBEC mutagenesis activity (Fig. 3d).